A Study of Amivantamab in People With Esophagogastric Cancer
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether the study drug, amivantamab, is an effective
treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will
also look at whether amivantamab is a safe treatment that causes few or mild side effects in
participants.